ELAN - ELAN FRAUD REVIEW: BFA Law Alerts Elanco (NYSE:ELAN) Investors that Lost Money to Contact Us about Securities Fraud Investigation | Benzinga
NEW YORK, July 03, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Elanco Animal Health Incorporated (NYSE:ELAN) for potential violations of the federal securities laws.
If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated.
Why Did Elanco's Stock Drop?
Elanco develops products to treat diseases in animals. Two of the most important treatments in the company's development pipeline are currently being reviewed by the U.S. Food and Drug Administration ("FDA"). The treatments are named Zenrelia, a drug for a type of dermatitis in dogs, and Credelio Quattro, which is a broad spectrum oral parasiticide covering fleas, ticks and internal parasites.
With respect to these treatments, the company stated that the FDA "has all data necessary to ...
ELAN) Investors that Lost Money to Contact Us about Securities Fraud Investigation>Full story available on Benzinga.com